Now Playing
Opinion|Videos|September 9, 2024
The Impact of CRM Diseases in the US: Burden, Prevalence, and Obesity
Key Takeaways
- CRM conditions significantly impact clinical outcomes and quality of life, increasing healthcare resource utilization.
- Obesity, prevalent in over 42% of adults, exacerbates the prevalence and impact of CRM conditions.
A panel of experts examines the impact of cardiometabolic diseases in the United States, focusing on their burden, prevalence, and relationship to obesity.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the clinical and economic burden of Cardiorenal Metabolic Disease (CRM) conditions such as type 2 diabetes, chronic kidney disease, cardiovascular disease and heart failure in the United States?
- How do CRM conditions affect patient quality of life and clinical outcomes?
- How do these conditions impact healthcare resource utilization?
- The CDC has announced that over 42% of adults have obesity; what role does obesity play in the prevalence of CRM conditions in the United States?
- Is this your experience in your practice?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
3
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
4
Value-Based Care Interventions and Management of CKD Progression
5
